Families waiting for new Alzheimer’s treatments are about to get a wave of data. Eight Phase 3 clinical trials, each testing a different drug or intervention, are scheduled to reach their primary ...

Biogen plans to advance an experimental drug for Alzheimer's disease to late-stage testing despite disappointing mid-stage trial data, the company said Thursday. Biogen plans to move the drug into ...

Along with knowing more about Alzheimer’s disease, public education needs to openly address the option of not having to live with it in the late stages.

Researchers have identified seven proteins in the blood that could enable better blood tests for Alzheimer's disease. A study shows that using a broader panel of markers provides a clearer picture of ...